TR201908127T4 - Hbv tedavisi. - Google Patents
Hbv tedavisi. Download PDFInfo
- Publication number
- TR201908127T4 TR201908127T4 TR2019/08127T TR201908127T TR201908127T4 TR 201908127 T4 TR201908127 T4 TR 201908127T4 TR 2019/08127 T TR2019/08127 T TR 2019/08127T TR 201908127 T TR201908127 T TR 201908127T TR 201908127 T4 TR201908127 T4 TR 201908127T4
- Authority
- TR
- Turkey
- Prior art keywords
- rnai
- agent
- hbv
- gene
- hepatitis
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 241000700721 Hepatitis B virus Species 0.000 abstract 3
- 239000012636 effector Substances 0.000 abstract 3
- 230000000295 complement effect Effects 0.000 abstract 2
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Control Of Eletrric Generators (AREA)
Abstract
Bu buluş, bir RNA interferans (RNAi) ajanı ve bu RNAi ajanının, bireylerde hepatit B enfeksiyonunun tedavisine yönelik kullanımının yanı sıra buluşa ait RNAi ajanlarını içeren farmasötik bileşimlere yöneliktir. RNAi ajanları veya bunları eksprese etmeye yönelik yapılar, en az bir Hepatit B virüsü (HBV) geninin ekspresyonunu inhibe etmek için kullanılır; burada ajan, bir hedef bölgeden kopyalanan öngörülmüş bir sekansa tamamlayıcı veya büyük ölçüde tamamlayıcı bir efektör sekans içerir. Buluşun bazı formlarında, ajan birden fazla efektör sekansa sahiptir. Çoklu efektörler, bir HBV geninin aynı bölgesini, aynı genin farklı (muhtemelen örtüşen) bölgelerini ve/ veya farklı HBV genlerini hedefleyebilir.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010522003.3A CN101979557B (zh) | 2010-10-28 | 2010-10-28 | 一种siRNA分子及其在抗病毒药物中的应用 |
CN201010521972.7A CN102021170B (zh) | 2010-10-28 | 2010-10-28 | 一种干扰乙型肝炎病毒基因的siRNA分子及其应用 |
CN201010521962.3A CN101979554B (zh) | 2010-10-28 | 2010-10-28 | 一种干扰HBV基因的siRNA分子及其应用 |
CN201010521975.0A CN101979555B (zh) | 2010-10-28 | 2010-10-28 | 一种小干扰rna分子及其应用 |
CN201010521948.3A CN101979553B (zh) | 2010-10-28 | 2010-10-28 | 一种干扰HBV基因的siRNA分子及其抗病毒应用 |
CN201010521990.5A CN101979556B (zh) | 2010-10-28 | 2010-10-28 | 一种siRNA靶向分子及其应用 |
CN201010522005.2A CN101979558B (zh) | 2010-10-28 | 2010-10-28 | 一种靶向乙型肝炎病毒基因的siRNA分子及其应用 |
PCT/CN2011/071107 WO2012109798A1 (en) | 2011-02-18 | 2011-02-18 | Hbv treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201908127T4 true TR201908127T4 (tr) | 2019-06-21 |
Family
ID=45993174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/08127T TR201908127T4 (tr) | 2010-10-28 | 2011-10-27 | Hbv tedavisi. |
Country Status (20)
Country | Link |
---|---|
US (2) | US9080174B2 (tr) |
EP (2) | EP3124610B1 (tr) |
KR (2) | KR20180110186A (tr) |
CN (1) | CN103370415B (tr) |
AU (1) | AU2011320437B2 (tr) |
BR (1) | BR112013010525A2 (tr) |
CA (1) | CA2853613C (tr) |
CY (1) | CY1121894T1 (tr) |
DK (1) | DK3124610T3 (tr) |
ES (1) | ES2730393T3 (tr) |
HR (1) | HRP20190995T1 (tr) |
HU (1) | HUE044426T2 (tr) |
LT (1) | LT3124610T (tr) |
PL (1) | PL3124610T3 (tr) |
PT (1) | PT3124610T (tr) |
RS (1) | RS58982B1 (tr) |
RU (1) | RU2620966C2 (tr) |
SI (1) | SI3124610T1 (tr) |
TR (1) | TR201908127T4 (tr) |
WO (1) | WO2012055362A1 (tr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201604074TA (en) | 2011-04-21 | 2016-07-28 | Isis Pharmaceuticals Inc | Modulation of hepatitis b virus (hbv) expression |
WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
CN105002214B (zh) * | 2015-04-08 | 2018-07-17 | 许中伟 | 用于载体表达的复合多联gRNA和RNAi的表达框架 |
JP7191690B2 (ja) * | 2015-05-06 | 2022-12-19 | ベニテック バイオファーマ リミテッド | B型肝炎ウイルス(hbv)感染を治療するための試薬及びその使用 |
CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
AU2017235278C1 (en) | 2016-03-14 | 2022-03-10 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of PD-L1 expression |
CN109415733A (zh) | 2016-05-05 | 2019-03-01 | 贝尼泰克生物制药有限公司 | 用于治疗乙型肝炎病毒(hbv)感染的药剂及其使用 |
MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
CN108929870B (zh) * | 2017-05-19 | 2020-01-24 | 百奥迈科生物技术有限公司 | 抑制HBV的siRNA分子及其应用 |
WO2019076842A1 (en) | 2017-10-16 | 2019-04-25 | F. Hoffmann-La Roche Ag | NUCLEIC ACID MOLECULE FOR THE REDUCTION OF PAPD5 AND PAPD7 MRNA FOR THE TREATMENT OF HEPATITIS B INFECTION |
WO2019193165A1 (en) | 2018-04-05 | 2019-10-10 | F. Hoffmann-La Roche Ag | Use of fubp1 inhibitors for treating hepatitis b virus infection |
BR112020026973A2 (pt) | 2018-07-03 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modulação da expressão tau |
SG11202100348SA (en) | 2018-07-13 | 2021-02-25 | Hoffmann La Roche | Oligonucleotides for modulating rtel1 expression |
CN114829601A (zh) | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 |
CN114901821A (zh) | 2019-12-19 | 2022-08-12 | 豪夫迈·罗氏有限公司 | Sept9抑制剂用于治疗乙型肝炎病毒感染的用途 |
EP4077671A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of saraf inhibitors for treating hepatitis b virus infection |
JP2023506547A (ja) | 2019-12-19 | 2023-02-16 | エフ. ホフマン-ラ ロシュ エージー. | B型肝炎ウイルス感染を処置するためのcops3阻害剤の使用 |
JP2023538630A (ja) | 2020-08-21 | 2023-09-08 | エフ. ホフマン-ラ ロシュ アーゲー | B型肝炎ウイルス感染症を処置するためのa1cf阻害剤の使用 |
TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 rtel1 表現之增強型寡核苷酸 |
WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
SG115493A1 (en) | 1998-03-20 | 2005-10-28 | Benitec Australia Ltd | Control of gene expression |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Rna干渉の方法とrna干渉組成物 |
US7919309B2 (en) | 2001-09-13 | 2011-04-05 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
JP2006515162A (ja) | 2002-08-29 | 2006-05-25 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 環状核酸ベクター、ならびに同ベクターの作製法および使用法 |
CA2527907A1 (en) | 2003-06-03 | 2004-12-09 | Benitec Australia Limited | Double-stranded hairpin rnas for rnai |
CN103060324B (zh) | 2004-03-05 | 2015-04-01 | 贝尼泰克生物制药有限公司 | 用于RNAi试剂同时递送的多启动子表达盒 |
WO2006084209A2 (en) | 2005-02-03 | 2006-08-10 | Benitec, Inc. | Rnai expression constructs |
US8008468B2 (en) * | 2005-02-16 | 2011-08-30 | Benitec, Inc. | RNAi expression constructs with liver-specific enhancer/promoter |
AR057252A1 (es) * | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
US8129510B2 (en) | 2006-03-30 | 2012-03-06 | The Board Of Trustees Of The Leland Stanford Junior University | Minigene expression cassette |
CN101684478B (zh) * | 2009-06-26 | 2012-02-29 | 武汉大学 | 一种串联表达小干扰rna重组慢病毒载体的构建方法 |
CN101979556B (zh) * | 2010-10-28 | 2015-01-21 | 百奥迈科生物技术有限公司 | 一种siRNA靶向分子及其应用 |
-
2011
- 2011-10-27 RS RS20190704A patent/RS58982B1/sr unknown
- 2011-10-27 DK DK16188642.9T patent/DK3124610T3/da active
- 2011-10-27 RU RU2013124422A patent/RU2620966C2/ru active
- 2011-10-27 KR KR1020187027763A patent/KR20180110186A/ko not_active Application Discontinuation
- 2011-10-27 AU AU2011320437A patent/AU2011320437B2/en not_active Ceased
- 2011-10-27 PT PT16188642T patent/PT3124610T/pt unknown
- 2011-10-27 WO PCT/CN2011/081386 patent/WO2012055362A1/en active Application Filing
- 2011-10-27 SI SI201131733T patent/SI3124610T1/sl unknown
- 2011-10-27 CN CN201180062884.8A patent/CN103370415B/zh not_active Expired - Fee Related
- 2011-10-27 CA CA2853613A patent/CA2853613C/en active Active
- 2011-10-27 BR BR112013010525A patent/BR112013010525A2/pt not_active Application Discontinuation
- 2011-10-27 EP EP16188642.9A patent/EP3124610B1/en active Active
- 2011-10-27 LT LTEP16188642.9T patent/LT3124610T/lt unknown
- 2011-10-27 PL PL16188642T patent/PL3124610T3/pl unknown
- 2011-10-27 HU HUE16188642 patent/HUE044426T2/hu unknown
- 2011-10-27 ES ES16188642T patent/ES2730393T3/es active Active
- 2011-10-27 TR TR2019/08127T patent/TR201908127T4/tr unknown
- 2011-10-27 EP EP11835635.1A patent/EP2633051B1/en not_active Not-in-force
- 2011-10-27 KR KR1020137013563A patent/KR101903778B1/ko active IP Right Grant
- 2011-10-27 US US13/882,124 patent/US9080174B2/en not_active Expired - Fee Related
-
2015
- 2015-06-05 US US14/731,824 patent/US9410154B2/en active Active
-
2019
- 2019-05-31 HR HRP20190995TT patent/HRP20190995T1/hr unknown
- 2019-06-03 CY CY20191100583T patent/CY1121894T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140071949A (ko) | 2014-06-12 |
HUE044426T2 (hu) | 2019-10-28 |
EP2633051A4 (en) | 2014-04-23 |
WO2012055362A1 (en) | 2012-05-03 |
US9410154B2 (en) | 2016-08-09 |
EP3124610B1 (en) | 2019-03-06 |
CA2853613C (en) | 2020-03-24 |
RU2620966C2 (ru) | 2017-05-30 |
BR112013010525A2 (pt) | 2016-08-02 |
RS58982B1 (sr) | 2019-08-30 |
AU2011320437A1 (en) | 2013-06-13 |
PT3124610T (pt) | 2019-06-14 |
ES2730393T3 (es) | 2019-11-11 |
EP2633051A1 (en) | 2013-09-04 |
CN103370415B (zh) | 2017-05-31 |
PL3124610T3 (pl) | 2019-09-30 |
HRP20190995T1 (hr) | 2019-08-09 |
RU2013124422A (ru) | 2014-12-10 |
CY1121894T1 (el) | 2020-10-14 |
US20150344885A1 (en) | 2015-12-03 |
KR20180110186A (ko) | 2018-10-08 |
CA2853613A1 (en) | 2012-05-03 |
US9080174B2 (en) | 2015-07-14 |
CN103370415A (zh) | 2013-10-23 |
DK3124610T3 (da) | 2019-06-11 |
LT3124610T (lt) | 2019-08-12 |
US20130296401A1 (en) | 2013-11-07 |
SI3124610T1 (sl) | 2019-08-30 |
AU2011320437B2 (en) | 2017-03-16 |
EP3124610A1 (en) | 2017-02-01 |
EP2633051B1 (en) | 2016-09-14 |
KR101903778B1 (ko) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201908127T4 (tr) | Hbv tedavisi. | |
MX2020011806A (es) | Agentes de iarn para infeccion causada por el virus de la hepatitis b. | |
JOP20210231A1 (ar) | مركبات ترابطية مستهدفة كمركبات علاجية | |
BR112013005872A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
EA201690497A3 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
WO2017027350A3 (en) | Rnai therapy for hepatitis b virus infection | |
BR112012024923A2 (pt) | "fosforamidatos de nucleosídeo, composição, comprimido, e seus usos" | |
CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
EA201600226A1 (ru) | Способы и композиции для рнк-направленного лечения вич-инфекции | |
IN2014CN03465A (tr) | ||
EA201301158A1 (ru) | Противовирусные соединения | |
MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
CO6450622A2 (es) | Agentes antiinflamatorios como compuestos virostáticos | |
WO2012079032A3 (en) | Compositions and methods of treating drug-resistant retroviral infections | |
EA201490643A1 (ru) | Новые производные бетулиновой кислоты с противовирусной активностью | |
IN2014CN03921A (tr) | ||
MX2013003698A (es) | Agente preventivo o terapeutico contra la fibrosis. | |
UA117563C2 (uk) | Композиція для лікування або профілактики хвороби, асоційованої з інфекцією впл | |
EA201490160A1 (ru) | Конструкции для сайленсинга гена p0 и применение | |
IN2013DE01960A (tr) | ||
EA201891427A1 (ru) | Нацеливающие лиганды для терапевтических соединений | |
Ala | THE DISTILLERY | |
CY1116324T1 (el) | Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη του καρκινου και ανοσων και αυτοανοσων νοσηματων | |
MY192896A (en) | N-[ (2 ` r) -2? ? deoxy-2? ?fluoro-2? ?methyl-p-phenyl-5? ?uridylyl] ?l-alanine 1-methylethyl ester and process for its production |